Cargando…

Persistence of SARS-CoV-2 total immunoglobulins in a series of convalescent plasma and blood donors

BACKGROUND: The vast majority of COVID-19 cases both symptomatic and asymptomatic develop immunity after COVID-19 contagion. Whether lasting differences exist between infection and vaccination boosted immunity is yet to be known. The aim of this study was to determine how long total anti-SARS-CoV2 a...

Descripción completa

Detalles Bibliográficos
Autores principales: Martin, M. Carmen, Jimenez, Ana, Ortega, Nuria, Parrado, Alba, Page, Isabel, Gonzalez, M. Isabel, Blanco-Peris, Lydia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8870513/
https://www.ncbi.nlm.nih.gov/pubmed/35202394
http://dx.doi.org/10.1371/journal.pone.0264124
_version_ 1784656775707885568
author Martin, M. Carmen
Jimenez, Ana
Ortega, Nuria
Parrado, Alba
Page, Isabel
Gonzalez, M. Isabel
Blanco-Peris, Lydia
author_facet Martin, M. Carmen
Jimenez, Ana
Ortega, Nuria
Parrado, Alba
Page, Isabel
Gonzalez, M. Isabel
Blanco-Peris, Lydia
author_sort Martin, M. Carmen
collection PubMed
description BACKGROUND: The vast majority of COVID-19 cases both symptomatic and asymptomatic develop immunity after COVID-19 contagion. Whether lasting differences exist between infection and vaccination boosted immunity is yet to be known. The aim of this study was to determine how long total anti-SARS-CoV2 antibodies due to past infection persist in peripheral blood and whether sex, age or haematological features can influence their lasting. MATERIAL AND METHODS: A series of 2421 donations either of SARS-CoV-2 convalescent plasma or whole blood from 1107 repeat donors from January 2020 to March 2021 was analysed. An automated chemiluminescence immunoassay for total antibodies recognizing the nucleocapsid protein of SARS-CoV-2 in human serum and plasma was performed. Sex, age, blood group, blood cell counts and percentages and immunoglobulin concentrations were extracted from electronic recordings. Blood donation is allowed after a minimum of one-month post symptom’s relapse. Donors were 69.7% males and their average age was 46. The 250 donors who had later donations after a positive one underwent further analysis. Both qualitative (positivity) and quantitative (rise or decline of optical density regarding consecutive donations) outcomes were evaluated. RESULTS AND DISCUSSION: In 97.6% of donors with follow-up, anti-SARS-CoV-2 protein N total antibodies remained positive at the end of a follow-up period of 12.4 weeks median time (1–46, SD = 9.65) after the first positive determination. The blood group was not related to antibody waning. Lower lymphocyte counts and higher neutrophils would help predict future waning or decay of antibodies. Most recovered donors maintain their total anti-SARS-CoV-2 N protein antibodies for at least 16 weeks (at least one month must have been awaited from infection resolution to blood donation). The 10 individuals that could be followed up longer than 40 weeks (approximately 44 weeks after symptom’s relapse) were all still positive.
format Online
Article
Text
id pubmed-8870513
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-88705132022-02-25 Persistence of SARS-CoV-2 total immunoglobulins in a series of convalescent plasma and blood donors Martin, M. Carmen Jimenez, Ana Ortega, Nuria Parrado, Alba Page, Isabel Gonzalez, M. Isabel Blanco-Peris, Lydia PLoS One Research Article BACKGROUND: The vast majority of COVID-19 cases both symptomatic and asymptomatic develop immunity after COVID-19 contagion. Whether lasting differences exist between infection and vaccination boosted immunity is yet to be known. The aim of this study was to determine how long total anti-SARS-CoV2 antibodies due to past infection persist in peripheral blood and whether sex, age or haematological features can influence their lasting. MATERIAL AND METHODS: A series of 2421 donations either of SARS-CoV-2 convalescent plasma or whole blood from 1107 repeat donors from January 2020 to March 2021 was analysed. An automated chemiluminescence immunoassay for total antibodies recognizing the nucleocapsid protein of SARS-CoV-2 in human serum and plasma was performed. Sex, age, blood group, blood cell counts and percentages and immunoglobulin concentrations were extracted from electronic recordings. Blood donation is allowed after a minimum of one-month post symptom’s relapse. Donors were 69.7% males and their average age was 46. The 250 donors who had later donations after a positive one underwent further analysis. Both qualitative (positivity) and quantitative (rise or decline of optical density regarding consecutive donations) outcomes were evaluated. RESULTS AND DISCUSSION: In 97.6% of donors with follow-up, anti-SARS-CoV-2 protein N total antibodies remained positive at the end of a follow-up period of 12.4 weeks median time (1–46, SD = 9.65) after the first positive determination. The blood group was not related to antibody waning. Lower lymphocyte counts and higher neutrophils would help predict future waning or decay of antibodies. Most recovered donors maintain their total anti-SARS-CoV-2 N protein antibodies for at least 16 weeks (at least one month must have been awaited from infection resolution to blood donation). The 10 individuals that could be followed up longer than 40 weeks (approximately 44 weeks after symptom’s relapse) were all still positive. Public Library of Science 2022-02-24 /pmc/articles/PMC8870513/ /pubmed/35202394 http://dx.doi.org/10.1371/journal.pone.0264124 Text en © 2022 Martin et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Martin, M. Carmen
Jimenez, Ana
Ortega, Nuria
Parrado, Alba
Page, Isabel
Gonzalez, M. Isabel
Blanco-Peris, Lydia
Persistence of SARS-CoV-2 total immunoglobulins in a series of convalescent plasma and blood donors
title Persistence of SARS-CoV-2 total immunoglobulins in a series of convalescent plasma and blood donors
title_full Persistence of SARS-CoV-2 total immunoglobulins in a series of convalescent plasma and blood donors
title_fullStr Persistence of SARS-CoV-2 total immunoglobulins in a series of convalescent plasma and blood donors
title_full_unstemmed Persistence of SARS-CoV-2 total immunoglobulins in a series of convalescent plasma and blood donors
title_short Persistence of SARS-CoV-2 total immunoglobulins in a series of convalescent plasma and blood donors
title_sort persistence of sars-cov-2 total immunoglobulins in a series of convalescent plasma and blood donors
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8870513/
https://www.ncbi.nlm.nih.gov/pubmed/35202394
http://dx.doi.org/10.1371/journal.pone.0264124
work_keys_str_mv AT martinmcarmen persistenceofsarscov2totalimmunoglobulinsinaseriesofconvalescentplasmaandblooddonors
AT jimenezana persistenceofsarscov2totalimmunoglobulinsinaseriesofconvalescentplasmaandblooddonors
AT orteganuria persistenceofsarscov2totalimmunoglobulinsinaseriesofconvalescentplasmaandblooddonors
AT parradoalba persistenceofsarscov2totalimmunoglobulinsinaseriesofconvalescentplasmaandblooddonors
AT pageisabel persistenceofsarscov2totalimmunoglobulinsinaseriesofconvalescentplasmaandblooddonors
AT gonzalezmisabel persistenceofsarscov2totalimmunoglobulinsinaseriesofconvalescentplasmaandblooddonors
AT blancoperislydia persistenceofsarscov2totalimmunoglobulinsinaseriesofconvalescentplasmaandblooddonors